The US FDA has approved four COVID vaccines targeting the XFG variant for the 2026-2027 season, developed by Moderna, Pfizer and BioNTech, Novavax, and Sanofi. While the vaccines are available for high-risk individuals, the CDC’s lack of guidance leads to… Read More »FDA approves four new COVID vaccines for the 2026-27 season
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran, significantly reduces melanoma recurrence and spread in a phase 3 trial. Combining intismeran with Merck’s Keytruda showed notable improvements in patient outcomes, marking a pivotal… Read More »New mRNA vaccine cuts recurrence and spread of melanoma
Moderna’s mRNA-1010 flu vaccine has received FDA approval for adults aged 50 and older, marking it as the first mRNA-based flu vaccine in the U.S. It demonstrates 26.6% higher effectiveness than standard vaccines. While adverse events were more frequent, most… Read More »FDA approves first mRNA flu vaccine for people over 50
A recent study reveals that an individualized mRNA vaccine for surgically resected melanoma, developed by Moderna and Merck, significantly reduces recurrence and distant spread risks over a five-year period. When combined with Keytruda, it boosts survival rates, showcasing the potential… Read More »Melanoma mRNA vaccine halves risk of recurrence, metastasis
A recent clinical trial revealed that Moderna’s mRNA flu vaccine showed a 26.6% higher effectiveness than standard flu vaccines among adults over 50. While it had more reported adverse effects, most were mild. Concerns persist about regulatory approval and acceptance,… Read More »Moderna mRNA flu vaccine more effective than standard shot
On February 10, 2026, the FDA denied Moderna’s biologics license application for its mRNA flu vaccine, citing insufficient trial data. After a meeting with Moderna on February 18, the FDA agreed to review a revised application, aiming for potential approval… Read More »FDA reverses itself and will review Moderna mRNA flu vaccine
On February 10, 2026, the FDA denied Moderna’s request for a biologics license application for its mRNA flu vaccine, mRNA-1010, citing inadequate trials. This refusal may hinder vaccine innovation and marketability in the U.S., reflecting concerns over anti-vaccine influences, particularly… Read More »FDA refused to review the Moderna mRNA flu vaccine application
The FDA has approved four COVID-19 vaccines for Fall 2025, including mRNA options from Moderna and Pfizer, and Novavax’s non-mRNA vaccine. Eligibility is primarily for individuals 65 and older, or 64 and younger with high-risk conditions. Healthcare providers may not… Read More »2025 COVID-19 vaccines FAQs — important questions answered
Rumors regarding HHS Secretary RFK Jr’s intent to eliminate COVID vaccines have surfaced, but the FDA approved new versions for Fall 2025. While vaccines are available for all individuals 65 and older, those under 64 must have high-risk conditions to… Read More »FDA approves Fall 2025 COVID vaccines with restrictions
HHS Secretary RFK Jr. has canceled over $500 million in mRNA vaccine funding, jeopardizing future vaccine development amidst ongoing health crises like bird flu. His anti-mRNA stance contradicts scientific evidence, risking delays in vital research. This decision threatens public health… Read More »RFK Jr cancels $500 million funding of mRNA vaccine research